PDS Biotechnology Corp (PDSB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PDS Biotechnology Corp (PDSB) has a cash flow conversion efficiency ratio of -1123.053x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.37 Billion) by net assets ($3.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PDSB defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
PDS Biotechnology Corp - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how PDS Biotechnology Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
PDS Biotechnology Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PDS Biotechnology Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CORESTEM Inc
KQ:166480
|
-0.103x |
|
Sreeleathers Limited
NSE:SREEL
|
0.037x |
|
Binh Duong Trade and Development JSC
VN:TDC
|
0.212x |
|
FIT INVEST JSC
VN:FIT
|
-0.015x |
|
Clipper Realty Inc
NYSE:CLPR
|
-0.076x |
|
San Neng Group Holdings Co Ltd
TW:6671
|
0.063x |
|
Orient Bell Limited
NSE:ORIENTBELL
|
0.037x |
|
DURECT CORP. DL-001
F:DC8A
|
N/A |
Annual Cash Flow Conversion Efficiency for PDS Biotechnology Corp (2012–2025)
The table below shows the annual cash flow conversion efficiency of PDS Biotechnology Corp from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see PDS Biotechnology Corp stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.25 Million | $-27.75 Billion | -2999.623x | -162637.71% |
| 2024-12-31 | $19.00 Million | $-35.03 Million | -1.843x | -43.19% |
| 2023-12-31 | $26.13 Million | $-33.64 Million | -1.287x | -120.31% |
| 2022-12-31 | $44.00 Million | $-25.71 Million | -0.584x | -195.79% |
| 2021-12-31 | $63.21 Million | $-12.49 Million | -0.198x | +59.24% |
| 2020-12-31 | $27.13 Million | $-13.15 Million | -0.485x | +68.63% |
| 2019-12-31 | $11.70 Million | $-18.07 Million | -1.545x | -39.06% |
| 2018-12-31 | $29.84 Million | $-33.15 Million | -1.111x | -70.28% |
| 2017-12-31 | $62.37 Million | $-40.70 Million | -0.652x | -80.97% |
| 2016-12-31 | $89.28 Million | $-32.19 Million | -0.361x | -103.01% |
| 2015-12-31 | $122.48 Million | $-21.75 Million | -0.178x | -150.89% |
| 2014-12-31 | $-27.83 Million | $-9.71 Million | 0.349x | -33.40% |
| 2013-12-31 | $-15.35 Million | $-8.04 Million | 0.524x | -21.03% |
| 2012-12-31 | $-3.38 Million | $-2.25 Million | 0.664x | -- |
About PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are… Read more